No efficacy data released yet; the stock is unlikely to move until topline results in late 2026. Monitor for any early leaks or presentations at medical conferences. The SWIFT-SC subcutaneous program adds optionality but remains early-stage.
Price Chart
Executive Summary
Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPARTA trial evaluating Prolastin-C in alpha-1 antitrypsin deficiency patients with emphysema. Topline results are expected by the end of 2026. This is a pipeline milestone with no financial data or efficacy readout yet.
Key Facts
- SPARTA Phase 3 trial completed last-patient-last-visit; topline results expected by end of 2026.
- Trial enrolled 345 participants across 37 sites in 16 countries.
- Evaluates two dose regimens of Prolastin-C (60 mg/kg and 120 mg/kg) vs placebo over three years.
- Primary endpoint is whole-lung CT densitometry, a sensitive measure of emphysema progression.
- Grifols also initiated SWIFT-SC Phase 3 trial for a subcutaneous alpha-1 proteinase inhibitor.
Financial Impact
No financial figures disclosed; commercial impact depends on topline results expected year-end 2026.
Risk Factors
- Topline results may fail to show statistically significant efficacy on CT densitometry endpoint.
- Even if positive, label expansion and market adoption for Prolastin-C may be limited.
- Competition from other augmentation therapies and subcutaneous formulations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341676 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $8.05 $7.75 | ▼ −3.73% | ▼ −2.81% | $7.32 (−9.07%) |
Jul 30, 2026 9w ago | 6-K | $8.20 $7.82 | ▼ −4.63% | ▼ −8.60% | $7.32 (−10.73%) |
Jul 16, 2026 11w ago | Press Release | $7.33 $7.93 | ▲ +8.19% | ▲ +4.57% | $7.32 (−0.14%) |
Jun 18, 2026 15w ago | 6-K | $7.28 $7.27 | ▼ −0.14% | ▲ +0.01% | $7.32 (+0.55%) |
Mar 17, 2026 28w ago | Press Release | $8.02 $8.69 | ▲ +8.35% | ▲ +4.05% | $7.32 (−8.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access